We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that in the ranks of the world's biggest cancer drug maker.
At $1.5 million, Frazier's base salary has remained steady for several years running. But his cash incentive pay more than doubled year-over-year, to $3.34 million.